ALEC - Alector Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

101M

Cash

562.1M

Avg Qtr Burn

-49.24M

Short % of Float

6.08%

Insider Ownership

8.98%

Institutional Own.

88.27%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Latozinemab (AL001) (progranulin) Details Frontotemporal dementia with a granulin mutation, Dementia	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AL101 (GSK4527226) (Progranulin) Details Parkinson's disease, Alzheimer's disease, Neurological disorder	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AL002 (TREM 2) Details Alzheimer's disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Latozinemab (AL001) (progranulin) Details Dementia, Frontotemporal dementia with C9orf72 mutation, Amyotrophic lateral sclerosis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AL003 (SIGLEC 3) Details Alzheimer's disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.